Experts Shoot Down Osaka’s Claim That Gargling Helps Beat Virus
(Bloomberg) -- Experts cast doubt over claims by officials in the city of Osaka that a gargling medicine could help treat coronavirus patients, even as shelves across Japan were stripped clean of popular brands.
There's not enough evidence to support Governor Hirofumi Yoshimura's claim that gargling with diluted povidone-iodine could prevent mild coronavirus patients from falling seriously ill, Toshio Nakagawa, chairman of the Japan Medical Association, told reporters Wednesday. The World Health Organization Centre for Health Development also added to skepticism.
“I understand that the governor must be very concerned about the sudden growth of cases in his region and is looking for some positive news,” said Nakagawa. “I don't intend to attack the claim as being inappropriate, but the position of our organization is that we should keep calm and research it.”
Yoshimura said at a briefing Tuesday that a study in Osaka had found gargling with diluted povidone-iodine four times a day reduced those testing positive in a group of 41 patients to just 9.5% after four days, compared with 40% for a group who gargled with just water. That announcement spurred panic buying of popular brands across the country, sending shares of producers and distributors soaring. They gave back most of those gains Wednesday.
The World Health Organization Centre for Health Development seemed to take a swipe at the claim in an infographic on its Twitter account Wednesday. “There's no scientific evidence that gargling medicine prevents the coronavirus,” it said.
“I never said a single word about it having a preventative effect,” Yoshimura told reporters Wednesday, saying the media needed to responsibly report the facts. He added that he was extremely skeptical about the treatment at first.
“But looking at the results, looking at those clear numbers -- for a drug that's accessible to everyone” and can bring patients closer to recovery, “it sounded like something that should be a lie, but it's true,” he said, while calling for people to avoid bulk-buying the formula.
The excitement and confusion over Yoshimura's announcement highlights the difficulty faced by the scientific community and politicians alike in dealing with the novel virus. As late as April, the WHO said that healthy people didn't need to wear face masks, a stance the body has now moderated. There has been debate over different treatments hailed as treatments for virus, from hydroxychloroquine to Fujifilm Holdings Corp.'s antiviral drug Avigan.
Povidone-iodine is an antiseptic more commonly known as betadine. In Japan, it's sold as gargles by Shionogi & Co., using the name Isojin under license from Mundipharma, as well as by Meiji Holdings Co. Shares in Meiji fell 3.8% in Tokyo, giving up almost all the gains from yesterday.
People in Japan commonly gargle as a preventative measure against colds and flus in winter, similar to hand-washing, though its effectiveness is still a matter of dispute. A 2005 study by Japanese scientists concluded gargling with water helped prevent upper respiratory tract infections, but didn't find using povidone-iodine any more effective than water, though a much smaller study on just 23 patients in 2003 did.
©2020 Bloomberg L.P.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.